1. “Comparison of sociodemographic, clinical and phenomenological charasteristics of Turkish and French patients suffering from obsessive-compulsive disorder,'' Can. J. Psychiatry, 45, 848, 2000
2. “Color and number preferences of patients with psychiatric disorders in Eastern Turkey,'' Percept Mot Skills, 94, 207-13, 2002
3. “Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive compulsive disorder,” Neuropsychobiology, 46, 27-32, 2002
4.“Antioxidant enzyme and malondialdehyde levels in patients with panic disorder,” Neuropyschobiology, 46, 186-9, 2002
5. “Serum leptin and cholesterol values in the suicide attempters,'' Neuropsychobiology, 45, 124-7, 2002
6. “Serum cholesterol and leptin values in patients with borderline personality disorder” Neuropsychobiology, 45, 167-71, 2002
7. “Weight gain and serum leptin levels in patients on lithium treatment,'' Neuropsychobiology, 46, 67-9, 2002
8. “Lipid peroxidation and antioxidant enzyme levels of patients with schizophrenia and bipolar disorder,'' Cell Biochem Funct, 20, 171-5, 2002
9. “Bone metabolism and bone mineral density in premenapausal women with mild depression,'' Yonsei Med J, 43, 101-8, 2002
10. “Serum leptine levels in patients with premature ejeculation,” Arch Andrology,48, 345-50, 2002
11. “Neopterin levels and dexamethasone supression test in posttraumatic stress disorder,” Eur Arch Psychiatry Clin Neurosci, 252, 161-5, 2002
12. “Sildenafil use in patients with olanzapine-induced erectile dysfunction,” Int. J. Impotance Res, 14, 547-9, 2002 (10 p)
13. “The efficacy of citalopram in the treatment of premature ejaculation: a placebo controlled study,” Int. J. Impotance Res, 14, 502-5, 2002
14. “Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings,” Hum. Psychopharmacol. Clin. Exp, 17, 401-5, 2002
15. “Serum leptin and cholesterol levels in the patients with bipolar disorder,” Neuropyschobiology, 46, 176-9, 2002
16. “Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidolin patients with schizophrenia,” Arch. Med. Res, 33, 562-5, 2002
17. “Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo- controlled study,'' Int. Clin. Psychopharmacol, 17, 115-9, 2002
18. “The detergent is circulating in my blood: A case report,” Int. J. Psychiatr. Clin. Pract, 6, 117-9, 2002
19. “Quetiapine-associated and dose related hypomania in a woman with schizophrenia,'' European Psychiatry, 17, 1-2, 2002
20. “Serum iron levels in schizophrenic patients with or without akathisia,” Eur. Neuropsychopharmacol, 13, 67-71, 2003
21. “Sociodemographic and clinical characteristics of patients with conversion disorder in Eastern Turkey,” Soc Psychiatr. Psychiatric Epidemiol, 38, 88-93, 2003
22. “Serum leptin levels in patients with premature ejaculation before and after citalopram treatment,” BJU Int, 91, 252-4, 2003
23. “Switching to tianeptine in patients with antidepressant-induced sexual dysfunction,” Hum Psychopharmacol Clin 18, 277-80, 2003.
24. “Neopterin production in posttraumatic stress disorder before and after pharmachotherapy,” Eur. Arch. Psychiatry Clin. Neurosci, 253, 34-6, 2003
25, “Free radicals in patients with post-traumatic stress disorder,” Eur. Arch. Psychiatry Clin. Neurosci, 253, 89-91, 2003
26. “Dissociative disorders in Turkish inpatients with conversion disorder,” Comp. Psychiatry, 44, 324-30, 2003
27. “Serum leptin and triglyceride levels in patients on antipsychotic treatment with atypical antipsychotics,” J. Clin. Psychiatry, 64, 598-604, 2003
28,“Nizatidine treatment and its relationship with leptin levels in patientts with olanzapine-induced weight gain,” Hum. Psychopharmacol. Clin. Exp, 18, 457-61, 2003
29. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, “Serum leptin and cholesterol levels in schizophrenic patients with and without suicide attempts”. Acta Psychiatr Scand. 108, 208-14, 2003
30.“ Weight gain, serum leptin and triglyceride levels in the patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol,” Schizophrenia Res, 60, 99-100, 2003
31. “An open clinical trial of reboxetine in the treatment of social phobia,” J. Clin. Psychopharmacol, 23, 417-9, 2003
32. “Nizatidine for the treatment of patients with quetiapine-induced weight gain”, Hum Psychopharmacol, 19:37-40 (2004)
33. “Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment,” Eur Arch Psychiatry Clin. Neurosci, 254, 231-35 (2004)
34. “A new atypical antipsychotic: quetiapine-induced sexual dysfunctions ”. Int. J. Impotance Res, 1-3 (2004)
35. “Serum leptin levels in obsessive-compulsive disorder,” Psychiatry and Clin. Neurosci, 59, 189-1 (2005)
36. “Serum folate and homocysteine levels in patients with obsessive-compulsive disorder,” Psychiatry and Clin. Neurosci, 59, 616-20 (2005)
37, “Plasma nitrate values in patients with obsessive-compulsive disorder,” Psychiatry and Clin. Neurosci, 59, 621-3 (2005)
38. “High serum leptin levels in depressive disorders with atypical features”. Psychiatry Clin Neurosci, 59:736-8(2005)
39. “The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin Neurosci, 59: 652-6 (2005)
40. “Hepatitis B and Hepatitis C virus infection in institutionalized schizophrenia and other psychotic disorders patients in Eastern Turkey” Neurology Psychiatry and Brain Research 13:159-64 (2006)
41. “Neopterin levels and dexamethasone supression test in obsessive-compulsive disorder,'' Psychiatry Res, 151: 265-70 (2007)
42. “The effects of antidepressant treatment on serum cholesterol and triglyceride levels in depressive patients” Neurology Psychiatry and Brain Research 14:13-8 (2007)
43. “Serum leptin and cholesterol values in violent and non-violent suicide attempters'' Psychiatry Res, 158: 87-91 (2008)
44. Antioxidant enzyme and malondialdehyde levels in patient with social phobia Psychiatry Res: 95-100 (2008)
45. “A left temporal lobe arachnoid cyst in a patient with schizophrenia-likepsychosis: A case report”. Prog Neuropsychopharmacol Biol Psychiatry. 32, 1349-50 (2008)
46. “Improvement from treatment-resistant schizoaffective disorder, manic type after stopping heavy caffeine intake: A case report''. Prog Neuropsychopharmacol Biol Psychiatry, 32, 1353-4 (2008)
47. “Arnold-Chiari I malformation association with generalized anxiety disorder: A case report'' Prog Neuropsychopharmacol Biol Psychiatry, 32, 1613-4 (2008)
48. “A case study of Neuro-psycho-Behçet's Syndrome presenting with psychotic attack”. Clin Neurol Neurosurg 111 (10), 877-9 (2009)
49. “Lamotrigine-induced obsessional symptoms in a patient with bipolar II disorder: A case report” J Psychopharmacol, 23(8), 1001-3 (2009)
50. “Obsessional symptoms associated with lamotrigine use in a patient with bipolar II disorder”. Klinik Psikofarmakoloji Bülteni /Bull Clin Psychopharmacol, 19, 414-6 (2009)
51. “Aripiprazole induced rabbit syndrome: A case report”. J Psychopharmacol, 24(3), 429-31 (2010)
52. “Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use”. J Psychopharmacol, 24, 623-24 (2010)
53. “Venlafaxine-associated nocturnal bruxism in a depressive patient succesfully treated with buspirone”. J Psychopharmacol, 24, 627-28 (2010)
54. “Phenomenology of delusions and hallucinations in patients with schizophrenia” Bull Clin Psychopharmacol, 20:204-212 (2010)
55. “Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature”. Arch Womens Ment Health. 13(5):443-447 (2010)
56. “Duloksetin Tedavisi Sırasında Gelişen Galaktore: Olgu Sunumu” Türk Psikiyatri Dergisi, 22(3):200-1 (2011)
57. “Ketiapinle Tedavi Edilen Olfaktor Referans Sendromlu Bir Olgu Sunumu” Bull Clin Psychopharmacol, 21(3):193-200 (2011)
58. “Şizofreni Alt Tiplerinde Serum IL-1β, IL-2, IL-6, IL-8 Düzeyleri” Bull Clin Psychopharmacol, 21(3):246-8 (2011)
59. “OKB ve Psikojenik Polidipsi Birlikteliği Olan Bir Borderline Erotomani Olgusu” Türkiye Klinikleri Tıp Bilimleri Dergisi, 32:271-5 (2012).
60. “Bupropion kullanımıyla oluşan görsel hallüsinasyon: Olgu Sunumu” Bull Clin Psychopharmacol, 22(2): 187-9 (2012).
61. “Olanzapine induced hair loss: a case report” Bull Clin Psychopharmacol, 22(4): 362-5 (2012).
62. “Multipl Skleroz Hastalarında Aleksitimi ile Mizaç ve Karakter Özellikleri” Nöropsikiyatri Arşivi/Archives of Neuropsychiatry 50: 34-39 (2013).
63. “Barbeksaklon Yoksunluğuna Bağlı Psikotik Bozukluk” Nöropsikiyatri Arşivi/Archives of Neuropsychiatry 50: 87-88 (2013).
64. Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: A preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 45:145-9 (2013).
65. “A Case of Catatonic Schizophrenia Treated Effectively with Aripiprazole” Bull Clin Psychopharmacol, 23: 25-60 (2013).
66. Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine. Neuropsychiatr Dis Treat. 9:1545-52 (2013).
67. Increased serum prolactin levels in drug-naive first-episode male patients with schizophrenia. Nord J Psychiatry. 2013.
68. Reduced serum brain-derived neurotrophic factor in patients with first onset vitiligo. Neuropsychiatr Dis Treat. 12;10:2361-7 (2014).
69. Neurological soft signs might be endophenotype candidates for patients with deficit syndrome schizophrenia. Neuropsychiatr Dis Treat. 29;11:2825-31 (2015)
70. Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome. Neuropsychiatr Dis Treat. 30;11:865-72 (2015).
71. Paliperidone palmitate use in pregnancy in a woman with schizophrenia. Archieves of Women's Mental Health. 2015;18(5):739-40.
72. Reliability and Validity of the Turkish Version of the Clinical Opiate Withdrawal Scale (COWS). Bulletin of Clinical Psychopharmacology. 2015; 25(3):267-71.
73. Predictors of Relapse in Patients with Opioid Addiction During Buprenorphine-Naloxone Maintenance Treatment. Journal of Addiction and Neuropharmacology. 2015; 1:1.
74. Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study. Neuropsychiatr Dis Treat. 2016; 12:1261-68.
75. Increased serum G72 protein levels in patients with schizophrenia: a potential candidate biomarker. Acta Neuropsychiatr. 2017; 29(2):80-86.
76. The relationship between second-to-fourth digit (2D:4D) ratios and problematic and pathological Internet use among Turkish university students. J Behav Addict. 2017; 6(1):30-41.
77. Intravenous buprenorphine/naloxone and concomitant oral pregabalin misuse: a case report. Neuropsychiatr Dis Treat. 2018 Nov 9;14:3033-3035.
78. Turkish adaptation of Kessler Psychological Distress Scale: validity and reliability study. Anatolian Journal of Psychiatry 2019; 20(Suppl.1):23-31)
79. The use of naltrexone implants for the treatment of opioid addiction: a retrospective study. Anatolian Journal of Psychiatry 2019; 20(2):133-138
80. Patients without psychopathology applying for aesthetic rhinoplasty may display elevated harm avoidance and reduced self-directedness: a crosssectional, case–control study. Psychiatry and Clinical Psychopharmacology, 2019.
© 2024, Prof. Dr. Murat KULOĞLU. Tüm Hakları Saklıdır.
Sosyal Ağ